Where would you like to sign in?

GlaxoSmithKline completes acquisition of Reliant Pharmaceuticals

LYSAKER, NORWAY--(Marketwire - December 20, 2007) - Pronova BioPharma ASA notes the
announcement made yesterday that GlaxoSmithKline PLC ("GSK") has
completed the acquisition of Reliant Pharmaceuticals Inc.
("Reliant"). This follows the US Federal Trade Commission's early
termination of the waiting period required by US antitrust law.

In a separate announcement released yesterday, GSK stated that with
the completion of the deal, Reliant's lead product, which is based on
Pronova BioPharma's API and branded as Lovaza in the US, joins the
GSK cardiovascular portfolio in the US. Lovaza is the only omega-3
derived pharmaceutical approved by the United States Food and Drug
Administration for the treatment of very high triglycerides.

"We're eager to begin building on Reliant's success with Lovaza. We
think this medicine has significant potential to help larger numbers
of patients, and we expect it to become an important driver of sales
growth in the US."

"We are pleased that GSK's acquisition of Reliant, whose lead product
is based on Pronova BioPharma's API, has been completed. We believe
GSK's ownership will be extremely beneficial for the sales of Lovaza
in the US. In addition, their commitment to Lovaza is a strong
endorsement of our API which is marketed as Omacor by a number of
other distribution partners outside of the US."